Sutent 25 mg Sunitinib Price USA | Ernest Impex Indian Exporter

Sutent 25mg Capsule: Gold Standard Tyrosine Kinase Inhibition for Global Oncology

Are you looking for a trusted Sutent 25 mg capsule exporter from India? Ernest Impex, a premier division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a high-authority global supplier and bulk distributor of innovator oncology brands. We facilitate a regulatory-compliant, cold-chain-secured supply chain serving Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), ensuring that life-saving cancer therapies reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Sutent 25 mg?

Sutent 25mg Capsule is a potent, oral, multi-targeted tyrosine kinase inhibitor (TKI) containing the active ingredient Sunitinib Malate. Developed by Pfizer, Sutent is an innovator medication that has revolutionized the treatment of specific solid tumors by targeting the pathways that allow cancer cells to grow and survive.

For international B2B procurement, Sutent 25 mg is a cornerstone treatment for advanced malignancies, particularly those that have become resistant to traditional chemotherapy.

Primary Therapeutic Indications

Sutent 25mg is clinically utilized across the globe for the following:

1. Gastrointestinal Stromal Tumor (GIST): For patients whose disease has progressed or who are intolerant to Imatinib Mesylate.

2. Advanced Renal Cell Carcinoma (RCC): Used as a primary treatment for metastatic kidney cancer.

3. Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors in patients with unresectable locally advanced or metastatic disease.

Mechanism of Action: Multi-Targeted Pathway Inhibition

Sutent works through a sophisticated pharmacological process known as Multi-Kinase Inhibition:

• Receptor Blockade: Sunitinib inhibits multiple receptor tyrosine kinases (RTKs), including all receptors for platelet-derived growth factors (PDGFRs) and vascular endothelial growth factors (VEGFRs).

• Anti-Angiogenesis: By blocking VEGFR, Sutent prevents the tumor from forming new blood vessels, effectively "starving" the tumor of the nutrients and oxygen required for expansion.

• Inhibiting Tumor Proliferation: It also targets the KIT (stem cell factor receptor) and FLT3, which are critical in the survival and growth of gastrointestinal and hematological malignancies.

• Dual-Action Efficacy: This simultaneous attack on both the tumor cells and the tumor blood supply makes it one of the most effective targeted therapies in modern oncology.

Administration and Clinical Safety

• Dosage: Sutent 25 mg is typically taken orally, once daily. For GIST and RCC, it is often administered on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2).

• Storage: Store at room temperature (20°C to 25°C). Ensure the container is tightly closed to protect from moisture.

• Key Monitoring Parameters:

• Hepatotoxicity: Liver function tests (ALT, AST, Bilirubin) must be monitored regularly.

• Cardiovascular Safety: Monitoring for left ventricular ejection fraction (LVEF) and hypertension is essential.

• Thyroid Function: Standard clinical practice includes screening for hypothyroidism.

• Dermatologic Safety: Patients should be monitored for Hand-Foot Skin Reaction (HFSR).

Why Source Sutent from Ernest Impex?

• Authentic Innovator Supply: Direct access to genuine Pfizer inventory, ensuring 100% product authenticity and competitive wholesale pricing for international markets.

• Global Logistics Expertise: We specialize in the complex documentation and cold-chain logistics required for shipping oncology medications to Washington, London, Bangkok, Canberra, Singapore, and Kingston.

• Regulatory Compliance: We provide all essential B2B documentation, including batch-specific COAs, GMP compliance, and necessary international export permits.

• Bulk Supply Reliability: We specialize in large-scale fulfillment for hospital networks, oncology centers, and regional pharmaceutical distributors.